Felise May Barte, MD
Glaucoma Specialist · Santa Clara, CANPI 1467658062
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,050 of the $121,045 with a category attached, or 71.1%. AbbVie accounts for 66.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $48,397 and has fallen 96.3% since, to $1,795 in 2025. Among glaucoma specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $384.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$81K
- Sight Sciences, Inc.$38K
- Alcon$647
- NEW World Medical,inc.$349
- Nova Eye, Inc.$218
- Bausch & Lomb Americas Inc.$208
- plus $647 from 12 others
What the payments were for
- Consulting fees$8,5507%
- Speaking & faculty fees$86,05071%
- Travel & lodging$17,65215%
- Food & beverage$8,7317%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 196 | $80,588 |
| Sight Sciences, Inc. | 70 | $38,389 |
| Alcon | 17 | $647 |
| NEW World Medical,inc. | 4 | $349 |
| Nova Eye, Inc. | 1 | $218 |
| Bausch & Lomb Americas Inc. | 3 | $208 |
| Ocular Therapeutix, Inc. | 4 | $105 |
| Harrow Eye, LLC | 1 | $100 |
| Glaukos Corporation | 4 | $99 |
| Thea Pharma Inc. | 4 | $77 |
| Tarsus Pharmaceuticals, Inc. | 2 | $77 |
| Novartis | 2 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Rxsight Inc | 1 | $27 |
| Ivantis, Inc | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$76,967
- OMNI(R) SURGICAL SYSTEM (US)$33,932
- TEARCARE SYSTEM$3,352
- SION SURGICAL INSTRUMENT$1,086
- XEN GLAUCOMA TREATMENT SYSTEM$1,050
- MIEBO$159
- XIIDRA$159
- VYZULTA$159
- Hydrus Microstent$145
- AcrySof IQ PanOptix$121
- LUMIGAN$119
- Rocklatan$119
- Kahook Dual Blade$118
- Clearpath$118
- Ahmed Glaucoma Valve$118
- Streamline$118
- IHEEZO$100
How this compares
$121,045 in reported general payments places this provider in the 95th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 341 | $173,322 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 62 | $25,026 |
| Latanoprost | 893 | $19,431 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $14,824 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 321 | $13,067 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $9,790 |
| Cyclosporine | 16 | $9,197 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $8,822 |
| RestasisCyclosporine | 13 | $7,710 |
| Bimatoprost | 45 | $7,541 |
| Travoprost | 44 | $7,325 |
| Prednisolone Acetate | 131 | $7,254 |
| Brimonidine Tartrate | 313 | $6,311 |
| Dorzolamide Hcl | 171 | $4,863 |
| Brinzolamide | 12 | $4,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $80,588 | $195,855387 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $12 | $9,79014 claims |
| AlconSimbrinza | $647 | $8,82236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Santa Clara
- Ricky CuiSanta Clara$1K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.